Truncus arteriosus is a congenital heart defect where a single, common arterial trunk arises from the heart, instead of the usual two separate vessels (the aorta and the pulmonary artery). Companies involved in this field may focus on various aspects, including medical devices, pharmaceuticals, and technologies related to the diagnosis, treatment, and management of truncus arteriosus.
Abbott Received FDA approval to initiate a first-in-human clinical trial evaluating its Amplatzer Amuletâ„¢ Occluder Device for transcatheter closure of the aortopulmonary connection in patients with Truncus Arteriosus. This minimally invasive approach could offer a less risky alternative to traditional open-heart surgery for TA repair.
Sapiens Announced positive preliminary results from its ongoing clinical trial assessing the safety and efficacy of its FORMAâ„¢ device for treating TA. The FORMA device aims to reconstruct the aortic arch and separate the pulmonary artery from the aorta, potentially offering a more definitive solution compared to other interventions.
The Truncus Arteriosus Research Consortium (TARC) collaborative group of researchers and clinicians is actively conducting studies to improve the understanding and treatment of TA. Recent efforts include developing standardized outcome measures and identifying genetic factors associated with the condition.
The American Heart Association (AHA) The AHA provides resources and support for families affected by TA and funds research aimed at improving diagnosis, treatment, and long-term outcomes for patients.
List of Truncus Arteriosus Key Companies in the Market
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)